• 1
    Steele RJ, Thompson AM, Hall PA, Lane DP. The p53 tumour suppressor gene. Br J Surg 1998; 85: 14607.
  • 2
    Hollstein M, Shomer B, Greenblatt M, Soussi T, Hovig E, Montesano R, Harris CC. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res 1996; 24: 1416.
  • 3
    Beroud C, Soussi T. p53 gene mutation: software and database. Nucleic Acids Res 1998; 26: 2004.
  • 4
    Bennett WP, Hussain SP, Vahakangas KH, Khan MA, Shields PG, Harris CC. Molecular epidemiology of human cancer risk: gene–environment interactions and p53 mutation spectrum in human lung cancer. J Pathol 1999; 187: 818.
  • 5
    Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 Database: new online mutation analysis and recommendations to users. Hum Mutat 2002; 19: 60714.
  • 6
    Mitsudomi T, Steinberg SM, Nau MM, Carbone D, D'Amico D, Bodner S, Oie HK, Linnoila RI, Mulshine JL, Minna JD, Gasdar AF. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 1992; 7: 17180.
  • 7
    Carbone DP, Mitsudomi T, Chiba I, Piantadosi S, Rusch V, Nowak JA, McIntire D, Slamon D, Gazdar A, Minna J. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. Chest 1994; 106: 377S381S.
  • 8
    Liloglou T, Ross H, Prime W, Donnelly RJ, Spandidos DA, Gosney JR, Field JK. p53 gene aberrations in non-small-cell lung carcinomas from a smoking population. Br J Cancer 1997; 75: 111924.
  • 9
    Brambilla E, Gazzeri S, Moro D, Caron de Fromentel C, Gouyer V, Jacrot M, Brambilla C. Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol 1993; 143: 199210.
  • 10
    Hashimoto T, Tokuchi Y, Hayashi M, Kobayashi Y, Nishida K, Hayashi S, Ishikawa Y, Tsuchiya S, Nakagawa K, Hayashi J, Tsuchiya E. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas. Cancer Res 1999; 59: 55727.
  • 11
    Hartmann A, Blaszyk H, McGovern RM, Schroeder JJ, Cunningham J, De Vries EM, Kovach JS, Sommer SS. p53 gene mutations inside and outside of exons 5–8: the patterns differ in breast and other cancers. Oncogene 1995; 10: 6818.
  • 12
    Casey G, Lopez ME, Ramos JC, Plummer SJ, Arboleda MJ, Shaughnessy M, Karlan B, Slamon DJ. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 1996; 13: 197181.
  • 13
    Brattstrom D, Bergqvist M, Lamberg K, Kraaz W, Scheibenflug L, Gustafsson G, Inganas M, Wagenius G, Brodin O. Complete sequence of p53 gene in 20 patients with lung cancer: comparison with chemosensitivity and immunohistochemistry. Med Oncol 1998; 15: 25561.
  • 14
    Tomizawa Y, Kohno T, Fujita T, Kiyama M, Saito R, Noguchi M, Matsuno Y, Hirohashi S, Yamaguchi N, Nakajima T, Yokota J. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma. Oncogene 1999; 18: 100714.
  • 15
    Kropveld A, Rozemuller EH, Leppers FG, Scheidel KC, de Weger RA, Koole R, Hordijk GJ, Slootweg PJ, Tilanus MG. Sequencing analysis of RNA and DNA of exons 1 through 11 shows p53 gene alterations to be present in almost 100% of head and neck squamous cell cancers. Lab Invest 1999; 79: 34753.
  • 16
    Loeb LA. Cancer cells exhibit a mutator phenotype. Adv Cancer Res 1998; 72: 2556.
  • 17
    Zhang H, Richards B, Wilson T, Lloyd M, Cranston A, Thorburn A, Fishel R, Meuth M. Apoptosis induced by overexpression of hMSH2 or hMLH1. Cancer Res 1999; 59: 30217.
  • 18
    Xinarianos G, Liloglou T, Prime W, Maloney P, Callaghan J, Fielding P, Gosney JR, Field JK. hMLH1 and hMSH2 expression correlates with allelic imbalance on chromosome 3p in non-small cell lung carcinomas. Cancer Res 2000; 60: 421621.
  • 19
    Benachenhou N, Guiral S, Gorska-Flipot I, Labuda D, Sinnett D. High resolution deletion mapping reveals frequent allelic losses at the DNA mismatch repair loci hMLH1 and hMSH3 in non-small cell lung cancer. Int J Cancer 1998; 77: 17380.
  • 20
    Liloglou T, Maloney P, Xinarianos G, Fear S, Field JK. Sensitivity and limitations of high throughput fluorescent microsatellite analysis for the detection of allelic imbalance: application in lung tumors. Int J Oncol 2000; 16: 514.
  • 21
    Lakin ND, Jackson SP. Regulation of p53 in response to DNA damage. Oncogene 1999; 18: 764455.
  • 22
    Scherer SJ, Welter C, Zang KD, Dooley S. Specific in vitro binding of p53 to the promoter region of the human mismatch repair gene hMSH2. Biochem Biophys Res Commun 1996; 221: 7228.
  • 23
    Scherer SJ, Maier SM, Seifert M, Hanselmann RG, Zang KD, Mueller-Hermelink HK, Angel P, Welter C, Schartl M. p53 and c-Jun functionally synergize in the regulation of the DNA repair gene hMSH2 in response to UV. J Biol Chem 2000; 345: 3746973.
  • 24
    Zhu YM, Das-Gupta EP, Russell NH. Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia. Blood 1999; 94: 73340.
  • 25
    Giarnieri E, Mancini R, Pisani T, Alderisio M, Vecchione A. Msh2, Mlh1, Fhit, p53, Bcl-2, and Bax expression in invasive and in situ squamous cell carcinoma of the uterine cervix. Clin Cancer Res 2000; 6: 36006.
  • 26
    Liloglou T, Scholes AG, Spandidos DA, Vaughan ED, Jones AS, Field JK. p53 mutations in squamous cell carcinoma of the head and neck predominate in a subgroup of former and present smokers with a low frequency of genetic instability. Cancer Res 1997; 57: 40704.
  • 27
    Field JK, Spandidos DA, Malliri A, Gosney JR, Yiagnisis M, Stell PM. Elevated p53 expression correlates with a history of heavy smoking in squamous cell carcinoma of the head and neck. Br J Cancer 1991; 64: 5737.
  • 28
    Field JK, Spandidos DA, Stell PM. Overexpression of p53 gene in head-and-neck cancer, linked with heavy smoking and drinking. Lancet 1992; 339: 5023.
  • 29
    de Anta JM, Jassem E, Rosell R, Martinez-Roca M, Jassem J, Martinez-Lopez E, Monzo M, Sanchez-Hernandez JJ, Moreno I, Sanchez-Cespedes M. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis. Oncogene 1997; 15: 29518.